Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

I understand, but that article and the preparation for it is literally my job field. My company is similar to the one that makes OncLive, and I can tell you all but certainly that they had a focus (the program was probably funded by Sanofi), and the guide for the discussion included a small nod toward future directions for the sake of balance.

He's acknowledging that Axal exists and that he's heard of it. That's good news, but in no way does it support the assertion that Axal outperforms checkpoint inhibitors. This article only supports that immunotherapy is going to continue to be important.